Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV002017095 | SCV002300301 | benign | Kabuki syndrome | 2022-11-22 | criteria provided, single submitter | clinical testing | |
Ce |
RCV003395357 | SCV004130811 | likely benign | not provided | 2023-05-01 | criteria provided, single submitter | clinical testing | KMT2D: PP2, BS2 |
Prevention |
RCV004538737 | SCV004712046 | uncertain significance | KMT2D-related disorder | 2023-12-06 | criteria provided, single submitter | clinical testing | The KMT2D c.3455C>T variant is predicted to result in the amino acid substitution p.Pro1152Leu. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0036% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Ambry Genetics | RCV004641887 | SCV005133503 | likely benign | Inborn genetic diseases | 2024-03-30 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Zotz- |
RCV003388082 | SCV004099335 | uncertain significance | Kabuki syndrome 1 | 2023-10-30 | no assertion criteria provided | clinical testing |